PR Newswire  | 

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

PR Newswire

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Theresa May während der Münchener Sicherheitskonferenz 2018.
Quelle: - Foto: Kuhlmann / MSC (https://commons.wikimedia.org/wiki/File:Theresa_May_MSC_2018.jpg), „Theresa May MSC ...
Novavax Inc 7,975 $ Novavax Inc Chart +0,69%
Zugehörige Wertpapiere:

GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:

Conference call details:
Date: May 6, 2026
Time: 8:30 a.m. ET
URL to register phone: Register Here
Dial-in number: (888) 880-3330 (U.S.) or

(+1) (646) 357-8766 (International)
Webcast: ir.novavax.com/events
  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details:
Date: Available starting at 11:30 a.m. ET, May 6, 2026, until 11:59 p.m. ET, May 13, 2026
Dial-in number: (800) 770-2030 (U.S.) or

(+1) (609) 800-9909 (International)
Passcode: 1309751#
Webcast: ir.novavax.com/events, until June 6, 2026

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Jim Kelly
844-668-2829
ir@novavax.com

Media
Yvonne Sprow
844-264-8571
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-first-quarter-2026-financial-results-on-may-6-2026-302757475.html

SOURCE Novavax, Inc.


Für dich aus unserer Redaktion zusammengestellt

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend